Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Accentia, Johns Hopkins co-host meeting with prospective clinical trial investigators at AAN meeting

Accentia Biopharmaceuticals, Inc. today announced that the Company and leading physicians from Johns Hopkins University co-hosted a meeting with prospective clinical trial investigators at the recent American Academy of Neurology (AAN) Annual Meeting in New Orleans.

7 May 2012

Gilead commences GS-1101 Phase 3 trial in CLL

Gilead Sciences, Inc. today announced that the first patient has been dosed in a Phase 3 clinical trial evaluating the efficacy and safety of GS-1101.

2 May 2012

CTI first quarter net loss decreases 66% to $17.4 million

Cell Therapeutics, Inc. today reported financial results and recent accomplishments for the first quarter of 2012.

21 Apr 2012

ImmunoGen commences IMGN529 Phase I trial in NHL

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN529 product candidate.

17 Apr 2012

Biovest seeks Health Canada approval of BiovaxID for follicular NHL

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that Biovest is seeking marketing approval in Canada for BiovaxID, its personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, an incurable cancer of the immune system.

10 Apr 2012

MD Anderson initiates Phase 1/2 entinostat-lapatinib ditosylate combination study in metastatic breast cancer

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that investigators at The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology have initiated a phase 1/2 study combining Syndax's lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin).

9 Apr 2012

Spectrum signs definitive agreement to acquire Allos

Spectrum Pharmaceuticals and Allos Therapeutics, Inc. today announced that they have signed a definitive agreement under which Spectrum will acquire all of the outstanding shares of Allos for $1.82 per share in cash plus one Contingent Value Right.

6 Apr 2012

Routine counseling on fertility preservation needed for young women with cancer

A new study has found that very few young women with cancer take steps to preserve their fertility while undergoing cancer therapy. Also, certain groups of young women are more likely to do so than others. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that efforts are needed to provide counseling on fertility preservation in reproductive-aged women diagnosed with cancer.

26 Mar 2012

New drug makes chemotherapy more effective in treating acute myeloid leukemia

Doctors at Washington University School of Medicine in St. Louis have shown that a new drug makes chemotherapy more effective in treating acute myeloid leukemia, a cancer of the white blood cells. Instead of attacking these cells directly, the drug helps drive them out of the bone marrow and into the bloodstream, where they are more vulnerable to chemotherapy.

21 Mar 2012

CTI fourth quarter net loss decreases to $17.9 million

Cell Therapeutics, Inc. today reported financial results and recent accomplishments for the fourth quarter and year ended December 31, 2011.

7 Mar 2012

Northern Ireland has higher survival rates for pancreatic cancer, leukaemia

The first audit of leukaemia treatment and survival in Northern Ireland by the Cancer Registry (NICR) at Queen's University Belfast has shown that survival rates for the disease here are at the highest levels since data collection began in 1993.

2 Mar 2012

Xencor, Boehringer Ingelheim partner to develop and supply biosuperior monoclonal antibodies

Xencor, Inc., a company using its proprietary Protein Design Automation (PDA) platform technology to engineer next-generation antibodies, and Boehringer Ingelheim announced today a collaboration agreement for certain Xencor biosuperior monoclonal antibodies.

21 Feb 2012

New immunotherapy combination prolongs survival in dogs with NHL

A new immunotherapy for companion dogs with advanced-stage non-Hodgkin lymphoma (NHL) has been shown to improve survival while maintaining quality of life, according to a study published in the journal Scientific Reports.

8 Feb 2012

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

Allos Therapeutics, Inc. today announced that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in January by the EMA's Committee For Medicinal Products for Human Use (CHMP) for conditional approval of FOLOTYN (pralatrexate injection) for the treatment of patients with peripheral T-cell lymphoma (PTCL) whose disease has progressed after at least one prior systemic therapy.

30 Jan 2012

Cell Therapeutics voluntarily withdraws Pixuvri NDA for NHL

Cell Therapeutics, Inc. announced today that it has voluntarily withdrawn its New Drug Application for Pixuvri (pixantrone) for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who failed two or more lines of prior therapy.

30 Jan 2012

Amgen enters definitive merger agreement to acquire Micromet

Amgen and Micromet, Inc. today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development (R&D) center in Munich and headquarters in Rockville, Md., for $11 per share in cash.

27 Jan 2012

Celgene signs definitive merger agreement to acquire Avila

Celgene Corporation and Avila Therapeutics, Inc., a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, today announced a definitive merger agreement under which Celgene Corporation will acquire Avila Therapeutics, Inc.

26 Jan 2012

Findings on cell working could lead to test and therapy for kidney failure caused by E. coli

New findings by St. Michael's researchers about the way cells work could lead to a test and therapy for kidney failure caused by E. coli

11 Jan 2012

New U.S. patent covers key element of Xencor's Xtend half-life prolongation technology

Xencor, Inc., a company using its proprietary Protein Design Automation (PDA) platform technology to engineer next-generation antibodies, announced today that the U.S. Patent and Trademark Office has issued Xencor a broad patent covering optimized monoclonal antibody variants and their application for extending in vivo half-life of antibodies.

7 Jan 2012

FDA sets Feb. 9 for ODAC meeting to review CTI's resubmitted pixantrone NDA

Cell Therapeutics, Inc. (CTI) announced today that on February 9, 2012 the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review CTI's resubmitted New Drug Application (NDA) for pixantrone for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) in patients who failed two or more lines of prior therapy.

3 Jan 2012

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Accentia, Johns Hopkins co-host meeting with prospective clinical trial investigators at AAN meeting

Gilead commences GS-1101 Phase 3 trial in CLL

CTI first quarter net loss decreases 66% to $17.4 million

ImmunoGen commences IMGN529 Phase I trial in NHL

Biovest seeks Health Canada approval of BiovaxID for follicular NHL

MD Anderson initiates Phase 1/2 entinostat-lapatinib ditosylate combination study in metastatic breast cancer

Spectrum signs definitive agreement to acquire Allos

Routine counseling on fertility preservation needed for young women with cancer

New drug makes chemotherapy more effective in treating acute myeloid leukemia

CTI fourth quarter net loss decreases to $17.9 million

Northern Ireland has higher survival rates for pancreatic cancer, leukaemia

Xencor, Boehringer Ingelheim partner to develop and supply biosuperior monoclonal antibodies

New immunotherapy combination prolongs survival in dogs with NHL

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

Cell Therapeutics voluntarily withdraws Pixuvri NDA for NHL

Amgen enters definitive merger agreement to acquire Micromet

Celgene signs definitive merger agreement to acquire Avila

Findings on cell working could lead to test and therapy for kidney failure caused by E. coli

New U.S. patent covers key element of Xencor's Xtend half-life prolongation technology

FDA sets Feb. 9 for ODAC meeting to review CTI's resubmitted pixantrone NDA

Everything you should know about lymphoma eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Everything you should know about lymphoma eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in